Sartorius AGSARTF -1.83%85 Median PS Value is $293.50 as of Jun. 24, 2026, which is 22305% above its 10-year median of 1.31. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $226.12 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 337 Medical Devices & Instruments companies, Sartorius AG ranks better than 53.41% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Sartorius AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $59.796. Sartorius AG's 10-Year median PS Ratio is 4.9084. Therefore, the Median PS Value for today is $293.50.
As of today (2026-06-24), Sartorius AG's share price is $192.43. Sartorius AG's Median PS Value is $293.50. Therefore, Sartorius AG's Price to Median PS Value for today is 0.66.
The historical rank and industry rank for Sartorius AG's Median PS Value or its related term are showing as below:
SARTF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.62 Med: 1.31 Max: 3.94
Current: 0.66
During the past 13 years, the highest Price to Median PS Value of Sartorius AG was 3.94. The lowest was 0.62. And the median was 1.31.
SARTF's Price-to-Median-PS-Value is ranked better than 53.41% of 337
companies
in the Medical Devices & Instruments industry
Industry Median: 0.7
vs SARTF: 0.66
Sartorius AG (OTCPK:SARTF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Sartorius AG's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
192.43
/
293.50
=
0.66
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG Median PS Value Related Terms
Sartorius AG Median PS Value Historical Data
* Premium members only.
The historical data trend for Sartorius AG's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SARTF vs ISRG, BDX, MDLN: Median PS Value Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Sartorius AG's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 4.9084.
Sartorius AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $59.796.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a Median PS Value of $293.50 as of Jun. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sartorius AG and its competitors. This is 22305% above median its historical median of 1.31. Over the past decade, Sartorius AG's Median PS Value has ranged from 0.62 to 3.94. According to the industry distribution chart, Sartorius AG ranks #157 out of 337 companies in the Medical Devices & Instruments industry, placing it in the top 46.6%.
Is Sartorius AG's Median PS Value too high?
Sartorius AG's current Median PS Value of $293.50 is 22305% above median its 10-year median of 1.31. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 3.94. The Medical Devices & Instruments industry median Median PS Value is 0.70. Sartorius AG's value of $293.50 is 41828.6% above this industry median. Based on the distribution chart, Sartorius AG ranks #157 out of 337 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Median PS Value compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #157 out of 337 companies for Median PS Value. This puts Sartorius AG in the upper half of its industry. The industry median Median PS Value is 0.70. Sartorius AG's value of $293.50 is 41828.6% above this benchmark. Historically, Sartorius AG's own Median PS Value has ranged from 0.62 to 3.94 over the past decade. While the company's 10-year median is 1.31 vs. the industry median of 0.70, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.70, based on 337 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current Median PS Value of $293.50 is 41828.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current Median PS Value is $293.50, which is 22305% above median its own 10-year median of 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $226.12, compared to a current price of $192.43 — trading 14.9% below its estimated fair value. The current Median PS Value is $293.50, which is 22305% above median its 10-year median of 1.31 and 41828.6% above the Medical Devices & Instruments industry median of 0.70. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Median PS Value is $293.50 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $192.43 is trading 14.9% below its estimated GF Value™ of $226.12.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
Median PS Value: $293.50 (22305% above median its 10-year median of 1.31)
GF Value™: $226.12 vs. price of $192.43 (14.9% below fair value)
Industry Position: 41828.6% above the Medical Devices & Instruments median (#157 of 337)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
